Literature DB >> 11355924

Prognostic factors in acute myeloid leukaemia.

B Löwenberg1.   

Abstract

The prognosis between subgroups of patients with acute myeloid leukaemia (AML) may range considerably. Haematological, genetic and clinical analysis has provided possibilities for defining the heterogeneity of prognosis. This furnishes clinically relevant insights into the probability of treatment response and survival in individual cases of AML and it provides a lead in treatment management. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11355924     DOI： 10.1053/beha.2000.0116

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  10 in total

1.  Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.

Authors:  Maha Atfy; Mohamad Eissa; Hossam E Salah; Deena A El Shabrawy
Journal:  Med Oncol       Date:  2011-06-03       Impact factor: 3.064

2.  More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Authors:  Guillermo Montalban-Bravo; Christopher B Benton; Sa A Wang; Farhad Ravandi; Tapan Kadia; Jorge Cortes; Naval Daver; Koichi Takahashi; Courtney DiNardo; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Sherry Pierce; Carlos Bueso-Ramos; Keyur Patel; Steven Kornblau; Hagop Kantarjian; Ken H Young; Guillermo Garcia-Manero; Michael Andreeff
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

3.  Hierarchy in gene expression is predictive of risk, progression, and outcome in adult acute myeloid leukemia.

Authors:  Shubham Tripathi; Michael W Deem
Journal:  Phys Biol       Date:  2015-02-16       Impact factor: 2.583

4.  Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

Authors:  Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

5.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

6.  Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.

Authors:  Lisa Pleyer; Reinhard Stauder; Sonja Burgstaller; Martin Schreder; Christoph Tinchon; Michael Pfeilstocker; Susanne Steinkirchner; Thomas Melchardt; Martina Mitrovic; Michael Girschikofsky; Alois Lang; Peter Krippl; Thamer Sliwa; Alexander Egle; Werner Linkesch; Daniela Voskova; Hubert Angermann; Richard Greil
Journal:  J Hematol Oncol       Date:  2013-04-29       Impact factor: 17.388

7.  Upregulated TCRζ improves cytokine secretion in T cells from patients with AML.

Authors:  Shaohua Chen; Xianfeng Zha; Li Shi; Lingling Zhou; Lijian Yang; Bo Li; Xiuli Wu; Jun Zhong; Tao Zhang; Yuhong Lu; Kanger Zhu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2015-06-18       Impact factor: 17.388

8.  Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

Authors:  Lisa Pleyer; Sonja Burgstaller; Michael Girschikofsky; Werner Linkesch; Reinhard Stauder; Michael Pfeilstocker; Martin Schreder; Christoph Tinchon; Thamer Sliwa; Alois Lang; Wolfgang R Sperr; Peter Krippl; Dietmar Geissler; Daniela Voskova; Konstantin Schlick; Josef Thaler; Sigrid Machherndl-Spandl; Georg Theiler; Otto Eckmüllner; Richard Greil
Journal:  Ann Hematol       Date:  2014-06-21       Impact factor: 3.673

9.  A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes.

Authors:  Xiaoyan Zhao; Yuan Li; Haibing Wu
Journal:  Int J Mol Med       Date:  2018-06-21       Impact factor: 4.101

10.  Prognostic significance of CXCR4 expression in acute myeloid leukemia.

Authors:  Wen Du; Cong Lu; Xinyun Zhu; Dong Hu; Xiangjun Chen; Juan Li; Wei Liu; Jiang Zhu; Yanli He; Junxia Yao
Journal:  Cancer Med       Date:  2019-09-13       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.